Welcome to another episode of Impact Unfiltered, where we dive deep into honest conversations with leaders creating real change in healthcare and beyond. In this special episode, the first of a three-part conversation, the tables turn as guest host Stuart Gilly interviews the show's own host, Philippe Pucheu, a doctor of pharmacy and founder and CEO of PBM Solutions who has spent his career on the front lines of drug pricing and access. Stuart opens with the question that anchors the whole series: what exactly is 340B, and why does it matter?
Together, they trace 340B from its 1992 origins to today's spotlight, unpacking how the federal drug pricing program works, the bad actors who divert its savings into new hospital wings instead of lowering patient costs, and why roughly 85 percent of purchases flow through big hospital systems rather than the FQHCs, clinics, and tribes it was built to help. Listeners will come away understanding what federally qualified health centers are, the headwinds threatening them, and Philippe's case that the biggest opportunity belongs to clinics that stay independent and give patients real, one-on-one time with their provider. Tune in for a jargon-free foundation to the series ahead.
1. Introduction to Impact Unfiltered and Episode Overview
- The podcast's mission: honest conversations with leaders creating real change in healthcare and beyond
- A special episode format in which the tables turn and guest host Stuart Gilly interviews the show's own host
- This is the first of a special three-part conversation with host Philippe Pucheu about his work
- Setting the theme: 340B, federally qualified health centers, and the fight for rural and underserved patient care
2. What Is 340B and Why It Matters
- Stuart opens by calling 340B a buzzword he has heard for years that few people fully understand
- Philippe defines it as a federal drug pricing program established in 1992 to help certain access-to-care providers lower prescription costs
- The core purpose is to lower the prescription cost passed on to the end user, the patient
- Technical complexities determine how a patient becomes eligible and which pharmacy they can use
- The program is now under the spotlight as a hot topic tied to the federal budget and pending changes
3. The Origins of 340B: Rural Access in 1992
- The program was created to protect rural access to care through FQHCs, critical access hospitals, and disproportionate share (DSH) hospitals
- Back then it targeted uninsured patients who, under the old system, still needed care these facilities had to provide
- It gave the federal government a way to let facilities purchase medications to offset the cost of uninsured or no-pay care
- The savings were meant to be used on the back end to discount the cost of uninsured care
4. The Disease States That Launched the Program
- Philippe points to diabetes as likely the number one driver as it came to light in the early 1990s
- Many diabetic medications at the time were injectable, before today's by-mouth options
- HIV and AIDS treatments were also hitting the market and helped catapult the program forward
- Today 340B can apply to nearly any medication, since it functions as a federal upper-limit price match
5. How 340B Pricing Actually Works
- The federal government sets a federally matched, upper-limit price on medications
- As a payer in the program, the government cannot be charged more than that negotiated, federally matched price
- That price reflects rebates and other pieces netted out
- As a result, some medications can come down to roughly a dollar for an entire dispensation
6. The Spotlight: Bad Actors and Misdirected Savings
- The current attention centers on bad actors taking 340B savings and revenue and spending them somewhere other than patient care and access
- Philippe points to the cranes and construction at major facilities: new wings, multi-story clinics, and outpatient surgery centers funded in part by 340B dollars
- Expanding a footprint or beautifying a campus does not lower the patient's cost at the door
- The intent was for those dollars to help people, expand access, and lower care costs, not to pad pockets or purchase provider groups
7. Who Really Uses 340B
- Roughly 85 percent of 340B purchases come from large hospital systems
- Only a small share goes to FQHCs, Ryan White clinics, tribes, and black lung programs
- Large not-for-profit hospital systems use their 340B leverage to also create revenue
- A 340B rebate program is set to kick off in 2027, which many hospital systems oppose
8. FQHCs and FQHC Look-Alikes Explained
- Hospital eligibility centers on inpatient care, while FQHCs are the outpatient, usually independently owned side
- A grant-funded FQHC, or grantee, is a non-profit that qualifies for grants that help the clinic grow and expand
- An FQHC look-alike is a non-grantee with a different status
- Both must meet accreditation standards, similar to JCAHO, and specific federal reporting requirements
- Most operate independently rather than as part of a larger health system
9. Who FQHCs Serve
- FQHCs generally sit outside metro areas, spread across rural and less-populated regions
- They aim to capture the care that falls outside big-city health systems, using Charlotte as an example
- They act as a stopgap where there is no family practice provider in the area
- The mission is to help rural and non-populous communities access care
10. The Headwinds Facing FQHCs
- FQHCs are getting the bad end of the stick because of hospitals and bad actors in the system
- Lower reimbursements squeeze their primary and specialty care
- They struggle to recruit and retain physicians who can earn more inside hospital systems
- They are essentially rowing their own boat to survive while hospital systems try to absorb them
11. The Compliance Burden and Finding the Right Partner
- As regulation, red tape, and reporting requirements flow down from hospitals to FQHCs, the compliance load grows
- FQHCs providing great care increasingly need someone to help manage compliance and reporting
- The right partner helps them stay within qualified status and in compliance with the law
- The danger is clinics asking whether the juice is worth the squeeze, risking the closures Philippe does not want to see
12. The Opportunity: Independence, More Services, One-on-One Care
- The biggest opportunity belongs to FQHCs that stand their own ground, add services, and expand independently of hospitals
- Patients are actively looking for one-on-one provider care
- Philippe critiques the rushed model where a provider spends five minutes and documents on a computer, driven by volume targets
- Patients need to sit down with their doctors and have time to explain what is happening to them
- He contrasts a private-equity-style push with genuine, independent provider care for chronic disease
13. Holistic Care and the Future of Better Patient Outcomes
- Philippe argues outcomes should be settled on data, comparing hospital outpatient clinics with FQHCs
- More time with providers can translate into better care and quality of life
- FQHCs often provide holistic care, avoiding fragmented referrals where several doctors treat a patient and none talk to each other
- Under an FQHC, an inter-collaborative team can work a patient's case together
- Stuart and Philippe close on the future of a well-run FQHC: better patient outcomes by bringing services in-house
